S95035 / Servier - LARVOL DELTA

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP (clinicaltrials.gov) - P1/2 | N=308 | Recruiting | Sponsor: Servier Bio-Innovation LLC | Phase classification: P1 ➔ P1/2 | N=27 ➔ 308 | Trial completion date: May 2026 ➔ Oct 2031 | Trial primary completion date: May 2026 ➔ Oct 2031

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

TRIAL IN PROGRESS: An open label phase I multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP (COSA 2024) - P1 | "Identification of predictive biomarkers and changes from baseline in intra-tumoral concentrations of SAM and MTA are key exploratory endpoints of the study. Clinical trial information (NCT06188702)"

Clinical • Metastases • P1 data • Oncology • Solid Tumor • MAT2A • MTAP

S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Servier Bio-Innovation LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Servier Bio-Innovation LLC

Metastases • New P1 trial • Oncology • Solid Tumor